Amyloid Plaques Ameliorate Memory Deficits and Hippocampal Neuron Loss in an Aβ4-42-Driven Alzheimer's Disease Mouse

Silvia Zampar1, Merle Fricke1, Florian Kremser1

  • 1Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg-August-University, Von-Siebold-Str. 5, 37075, Göttingen, Germany.

Insights

Amyloid plaques may buffer toxic soluble amyloid-beta oligomers in Alzheimer's disease (AD). Crossing mouse models showed plaques rescued memory deficits and reduced neuron loss, supporting oligomers' role in AD.

Area of Science:

  • Neuroscience
  • Pathology
  • Molecular Biology

Background:

  • Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) plaques.
  • Soluble Aβ oligomers, not plaques, are increasingly implicated as the primary neurotoxic species in AD.
  • N-terminally truncated Aβ variants, like Aβ4-42, are abundant in AD brains.

Purpose of the Study:

  • To investigate the relationship between soluble Aβ4-42 and insoluble Aβ deposits.
  • To determine if amyloid plaques act as reservoirs for toxic Aβ oligomers.

Main Methods:

  • Crossed Tg4-42hom mice (expressing Aβ4-42, no plaques) with 5XFAD mice (plaque-bearing).
  • Assessed spatial and recognition memory.
  • Evaluated CA1 pyramidal neuron loss in the hippocampus.
  • Quantified insoluble Aβ peptide levels.

Main Results:

  • Extracellular amyloid deposits did not worsen spatial memory but rescued recognition memory deficits.
  • Proximal CA1 neuron loss was unaffected, but distal neuron loss was reduced.
  • A trend towards increased insoluble Aβ4-x peptides was observed in the hippocampus.

Conclusions:

  • Findings support the critical role of soluble Aβ oligomers in AD pathogenesis.
  • Evidence suggests amyloid plaques may provide a buffering capacity, sequestering toxic oligomers.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...